No Data
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
CHUNLI MEDICAL (688236.SH): A total of 12.0189 million yuan has been used to repurchase company shares.
On April 2, Gelonghui reported that CHUNLI MEDICAL (688236.SH) announced that as of March 31, 2025, the company had repurchased a total of 868,145 shares through the centralized bidding trading method on the Shanghai Exchange, accounting for 0.226% of the company's total equity. The highest repurchase price was 15.96 yuan per share, the lowest price was 12.09 yuan per share, and the total amount of funds paid was 12.0189 million yuan (excluding transaction fees).
Hong Kong stocks movement | CHUNLI MEDICAL (01858) is currently up over 7%. The company's Overseas Business revenue has increased by 78% year-on-year, and the domestic Business is expected to gradually recover from the impact of centralized procurement.
CHUNLI MEDICAL (01858) is currently up over 7%, as of the time of publishing, up 6.42%, priced at HKD 9.95, with a trading volume of HKD 12.499 million.
2024 Annual Report
2024 Annual Report Summary
